Gensight Biologics Valuation
| SIGHT Stock | EUR 0.24 0.02 7.69% |
Gensight Biologics seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Gensight Biologics from evaluating the firm fundamentals such as Return On Equity of -1.72, shares outstanding of 46.16 M, and Return On Asset of -0.39 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Gensight Biologics' price fluctuation is out of control at this time. Calculation of the real value of Gensight Biologics is based on 3 months time horizon. Increasing Gensight Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Gensight Biologics' intrinsic value may or may not be the same as its current market price of 0.24, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.24 | Real 0.21 | Hype 0.24 | Naive 0.26 |
The intrinsic value of Gensight Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gensight Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gensight Biologics SA helps investors to forecast how Gensight stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gensight Biologics more accurately as focusing exclusively on Gensight Biologics' fundamentals will not take into account other important factors: Gensight Biologics Total Value Analysis
Gensight Biologics SA is at this time projected to have takeover price of 150.19 M with market capitalization of 144.58 M, debt of 12.1 M, and cash on hands of 44.29 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Gensight Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
150.19 M | 144.58 M | 12.1 M | 44.29 M |
Gensight Biologics Investor Information
About 13.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.68. Gensight Biologics had not issued any dividends in recent years. Based on the key indicators related to Gensight Biologics' liquidity, profitability, solvency, and operating efficiency, Gensight Biologics SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Gensight Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Gensight Biologics has an asset utilization ratio of 9.31 percent. This connotes that the Company is making €0.0931 for each dollar of assets. An increasing asset utilization means that Gensight Biologics SA is more efficient with each dollar of assets it utilizes for everyday operations.Gensight Biologics Ownership Allocation
Gensight Biologics SA has a total of 46.16 Million outstanding shares. 30% of Gensight Biologics outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Gensight Biologics Profitability Analysis
The company reported the revenue of 5.28 M. Net Loss for the year was (28.62 M) with profit before overhead, payroll, taxes, and interest of 7.71 M.About Gensight Biologics Valuation
The stock valuation mechanism determines Gensight Biologics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Gensight Biologics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Gensight Biologics. We calculate exposure to Gensight Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Gensight Biologics's related companies.GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. GENSIGHT BIOLOGICS is traded on Paris Stock Exchange in France.
8 Steps to conduct Gensight Biologics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Gensight Biologics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Gensight Biologics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Gensight Biologics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Gensight Biologics' revenue streams: Identify Gensight Biologics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Gensight Biologics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Gensight Biologics' growth potential: Evaluate Gensight Biologics' management, business model, and growth potential.
- Determine Gensight Biologics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Gensight Biologics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.